Tuesday, August 26, 2025

 

Cognitive Behavioural therapy can alter brain structure and boost grey matter volume, study shows



THE LITTLE GREY CELLS -- POIROT


Martin-Luther-Universität Halle-Wittenberg




Psychotherapy leads to measurable changes in brain structure. Researchers at Martin Luther University Halle-Wittenberg (MLU) and the University of Münster have demonstrated this for the first time in a study in “Translational Psychiatry” by using cognitive behavioural therapy. The team analysed the brains of 30 patients suffering from acute depression. After therapy, most of them showed changes in areas responsible for processing emotions. The observed effects are similar to those already known from studies on medication.

Around 280 million people suffer from severe depression worldwide. This depression leads to changes in the brain mass of the anterior hippocampus and amygdala. Both areas are part of the limbic system and are primarily responsible for processing and controlling emotions. In psychotherapy, cognitive behavioural therapy (CBT) is an established method for treating depression. “CBT leads to positive changes in thought patterns, emotions and behaviour. We assume that this process is also linked to functional and structural changes in the brain. The effect has already been demonstrated with therapy involving medication or electrostimulation, but has not yet been proven for psychotherapy in general,” says Professor Ronny Redlich, who heads the Department of Biological and Clinical Psychology at MLU.

Now researchers at MLU and the University of Münster have succeeded in demonstrating this in an extensive study involving 30 people suffering from acute depression. Structural magnetic resonance imaging (MRI) was used to examine the participants’ brains before and after 20 sessions of therapy. “MRI scans provide information about the size, shape and location of tissue,” explains psychologist Esther Zwiky from MLU. In addition to the MRI scans, clinical interviews were conducted to analyse the symptoms of the disease, such as difficulty in identifying and describing feelings. In addition, 30 healthy control subjects, who did not undergo therapy, participated in the study for comparison purposes.

The study provided clear results: 19 of the 30 patients were found to have hardly any acute depressive symptoms after therapy. The researchers were also able, for the first time, to document specific anatomical changes. “We observed a significant increase in the volume of grey matter in the left amygdala and the right anterior hippocampus,” says Esther Zwiky. The researchers found a clear connection to the symptoms: individuals with a greater increase in grey matter in the amygdala also showed a stronger reduction in their emotional dysregulation.

“Cognitive behavioural therapy was already known to work. Now, for the first time, we have a reliable biomarker for the effect of psychotherapy on brain structure. Put simply, psychotherapy changes the brain,” explains Ronny Redlich. However, Redlich stresses that there is no fundamentally better or worse treatment – medication works better for some people, while electrostimulation works very well for others; for others, CBT can be most helpful. “It is therefore all the more encouraging that we were able to show in our study that psychotherapy is an equally effective alternative from a medical and scientific standpoint,” says Redlich.

The study was supported German Research Foundation (DFG), the Federal Ministry of Research, Technology and Space (BMFTR) and the state of Saxony-Anhalt.

Study: Zwiky E. et al. Limbic gray matter increases in response to cognitive behavioural therapy in major depressive disordner. Translational Psychiatry (2025). doi: 10.1038/s41398-025-03545-7

 

Largest ever study into cannabis use investigates risk of paranoia and poor mental health in the general population




King's College London






New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, in partnership with the University of Bath, has found that the reasons why a person chooses to use cannabis can increase their risk of developing paranoia. 

The use and potency of cannabis is increasing worldwide, and dependence and cannabis-induced psychosis are also greatly increasing as a result, especially in North America. Two new research papers, both using data from Cannabis & Me - the largest survey of its kind - have identified key risk factors associated with the more severe forms of paranoia in cannabis users. 

The first study, published today in the BMJ Mental Health, explored the relationship between why people first started using cannabis, and how this affected their subsequent use.  

3389 former and current cannabis users aged 18 and over responded to a survey examining their reasons for first and continued use, their weekly consumption of cannabis in THC units, and their mental health. 

Researchers established several key findings. Respondents who first started using cannabis to self-medicate an illness, including physical pain, anxiety, depression, or because they were experiencing minor psychotic symptoms, all demonstrated higher paranoia scores.  

This was in contrast to those respondents who tried cannabis for fun or curiosity, or with their friends, who reported the lowest average paranoia and anxiety scores.  

Dr Edoardo Spinazzola, a Research Assistant at King’s IoPPN and the study’s first author said, “Our study provides vital evidence on how the reason someone first starts using cannabis can dramatically impact their long-term health.  

“This research suggests that using cannabis as a mean to self-medicate physical or mental discomfort can have a negative impact on the levels of paranoia, anxiety, and depression. Most of these subgroups had average scores of depression and anxiety which were above the threshold for referral to counselling." 

Respondents were also asked to provide data on the frequency and strength of the cannabis they were using so that researchers could track their average weekly consumption of Tetrahydrocannabinol (THC) - the principle psychoactive component of cannabis. 

The researchers found that the average respondent consumed 206 units of THC a week. This might equate to roughly 10-17 ‘joints’ per week, if the user was consuming an expected 20 per cent THC content that is standard for the most common types of cannabis available in London. 

However, respondents who started using cannabis to help with their anxiety, depression, or in cases where they started due to others in their household who were already using cannabis, reported on average 248, 254.7, and 286.9 average weekly THC units respectively. 

Professor Tom Freeman, Director of the Addiction and Mental Health Group at the University of Bath and one of the study’s authors said, “A key finding of our study is that people who first used cannabis to manage anxiety or depression, or because a family member was using it, showed higher levels of cannabis use overall.  

“In future, standard THC units could be used in a similar way to alcohol units – for example, to help people to track their cannabis consumption and better manage its effects on their health.” 

In a separate study, published in Psychological Medicine, researchers explored the relationship between childhood trauma, paranoia and cannabis use.  

Researchers used the same data set from the Cannabis & Me survey, with just over half of respondents (52 per cent) reporting experience of some form of trauma.  

Analysis established that respondents who had been exposed to trauma as children reported higher average levels of paranoia compared to those who hadn’t, with physical and emotional abuse emerging as the strongest predictors.  

Researchers also explored the relationship between childhood trauma and weekly THC consumption. Respondents who reported experience of sexual abuse had a markedly higher weekly intake of THC, closely followed by those who reported experiencing emotional and physical abuse. 

Finally, the researchers confirmed that the strong association between childhood trauma and paranoia is further exacerbated by cannabis use, but is affected by the different types of trauma experienced. Respondents who said they had experienced emotional abuse or household discord1 were strongly associated with increased THC consumption and paranoia scores. Respondents reporting bullying, physical abuse, sexual abuse, physical neglect and emotional neglect on the other hand did not show the same effects.  

Dr Giulia Trotta, a Consultant Psychiatrist and Researcher at King’s IoPPN and the study’s first author said, “This comprehensive study is the first to explore the interplay between childhood trauma, paranoia, and cannabis use among cannabis users from the general population. 

“We have not only established a clear association between trauma and future paranoia, but also that cannabis use can further exacerbate the effects of this, depending on what form the trauma takes.  

“Our findings will have clear implications for clinical practice as they highlight the importance of early screening for trauma exposure in individuals presenting with paranoia.” 

Professor Marta Di Forti, Professor of Drug use, Genetics and Psychosis at King’s IoPPN, Clinical Lead at the South London and Maudsley NHS Foundation Trust’s Cannabis Clinic for Patients with Psychosis, and the senior author on both studies said, “There is extensive national and internation debate about the legality and safety of cannabis use.  

“My experience in clinic tells me that there are groups of people who start to use cannabis as a means of coping with physical and emotional pain. My research has confirmed that this is not without significant further risk to their health and wellbeing, and policy makers across the world should be mindful of the impact that legalisation , without adequate public education and health support, could have on both the individual, as well as on healthcare systems more broadly.” 

Cannabis & Me was possible thanks to funding from the Medical Research Council (MRC). 

Ends 

For more information, please contact Patrick O’Brien (Media Manager) on 020 7848 5377. 

Are reasons for first using cannabis associated with subsequent cannabis consumption (standard THC units) and psychopathology? (Spinazzola, Di Forti et al) (DOI ) was published in BMJ Mental Health. Published 27/08/25 

The impact of Childhood Trauma and Cannabis Use on Paranoia: A Structural Equation Model Approach (Trotta, Di Forti et al) (DOI 10.1017/S0033291725101190) was published in Psychological Medicine.  Published 08/08/25 

  1. Household discord refers to living in a space where there is disharmony, conflict, or disagreement within a family unit 

About King’s College London and the Institute of Psychiatry, Psychology & Neuroscience  

King’s College London is amongst the top 35 universities in the world and top 10 in Europe (THE World University Rankings 2023), and one of England’s oldest and most prestigious universities.   

With an outstanding reputation for world-class teaching and cutting-edge research, King’s maintained its sixth position for ‘research power’ in the UK (2021 Research Excellence Framework). 

King's has more than 33,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff. The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s is a leading centre for mental health and neuroscience research in Europe. It produces more highly cited outputs (top 1% citations) on psychiatry and mental health than any other centre (SciVal 2021), and on this metric has risen from 16th (2014) to 4th (2021) in the world for highly cited neuroscience outputs. In the 2021 Research Excellence Framework (REF), 90% of research at the IoPPN was deemed ‘world leading’ or ‘internationally excellent’ (3* and 4*). World-leading research from the IoPPN has made, and continues to make, an impact on how we understand, prevent and treat mental illness, neurological conditions, and other conditions that affect the brain. 

www.kcl.ac.uk/ioppn | Follow @KingsIoPPN on TwitterInstagramFacebook and LinkedIn 

About the University of Bath 

 

The University of Bath is one of the UK's leading universities, recognised for high-impact research, excellence in education, an outstanding student experience and strong graduate prospects. 

  • We are ranked in the top 10 in all of the UK’s major university guides.  

  • The University achieved a triple Gold award in the last Teaching Excellence Framework 2023, the highest awards possible, for both the overall assessment and for student outcomes and student experience. The Teaching Excellence Framework (TEF) is a national scheme run by the Office for Students (OfS). 

  • We are also ranked among the top 10% of universities globally, placing 132nd in the QS World University Rankings 2026.  

Research from Bath is helping to change the world for the better. Across the University’s three Faculties and School of Management, our research is making an impact in society, leading to low-carbon living, positive digital futures, and improved health and wellbeing. Find out all about our Research with Impact: https://www.bath.ac.uk/campaigns/research-with-impact/ 

 

Optimization of biosafety laboratory management via an AI-driven intelligent system




FAR Publishing Limited
Evaluation of LLMs performance on 60 text-based questions and 8 image-based questions related to biosafety laboratories. 

image: 

The performance of Gemini Pro (A), Claude-3 (B), Claude-2 (C), GPT-4 (D), GPT-3.5 (E), Gemini Pro Vision (F), and GPT-4V (G). The right side of the figure displays, from top to bottom, the strict accuracy (the proportion of questions answered correctly all three times), overall accuracy (the proportion of questions answered correctly at least twice), and ideal accuracy (the proportion of questions answered correctly at least once). (H) The bar chart illustrates the comparative performance of LLMs in responding to text-based queries. (I) The bar chart depicts the comparative performance of LLMs in addressing image-based inquiries. LLMs: Large language models; RAAR: Reference answer accuracy rate; SAAR: Subjective answer accuracy rate; SAR: Strict accuracy rate.

view more 

Credit: Chang Qi, Anqi Lin, Anghua Li, Peng Luo, Shuofeng Yuan




ChatGPT and other generative AI models have achieved notable progress in natural language processing and generation, showing great potential in the medical field, such as automatically generating medical exam questions and answers, acting as personalized learning assistants, supporting course design, and aiding in medical imaging analysis. These models are also expected to be pivotal in training biosafety laboratory researchers by providing interactive learning experiences.

In this study, a dataset of 62 text-based and 8 image-based biosafety questions was collected from leading medical schools, HKU, and the US CDC. For text-based questions, Gemini Pro, Claude-3, Claude-2, GPT-4, and GPT-3.5 were evaluated, while Gemini Pro Vision and GPT-4V were used for image-based questions. Each model generated three responses per question, and metrics such as Reference Answer Accuracy Rate (RAAR), Subjective Answer Accuracy Rate (SAAR), and Strict Accuracy Rate (SAR) were used to analyze performance.

Results showed excellent performance for all models on text-based questions: Gemini Pro reached a RAAR of 79.4%, Claude-3 78.7%, Claude-2 76.5%, GPT-4 75.7%, and GPT-3.5 70.3%. For image-based questions, GPT-4V outperformed Gemini Pro, with RAARs of 78.7% and 76.5% respectively. Multimodal AI models like ChatGPT-4 and Gemini enabled real-time laboratory monitoring, anomaly detection, predictive maintenance, and improved biosafety training and education through automatic generation of customized materials.

However, generative AI faces limitations such as bias, errors, incomplete results, lack of high-quality training data for rare events, inadequate real-time processing, and ethical concerns like privacy and transparency. Addressing these challenges requires uncertainty markers, automated bias detection, human-AI collaborative verification, standardized and simulated datasets, federated learning, explainable AI, and robust accountability mechanisms. 

MISOGYNISTIC MEDICINE

Access to vaginal labor after C-section is limited to some 16% of U.S. counties


UMass Amherst research examined birth certificate data from 2016-21 and found access to the delivery option is not expanding, with ‘extremely limited access’ in South and Midwest


C- SECTION  PUTTING ZIPPERS IN WOMEN




University of Massachusetts Amherst

Senior author 

image: 

Laura Attanasio is an associate professor of health policy and management in the UMass Amherst School of Public Health and Health Sciences.

view more 

Credit: UMass Amherst





Only 16% of all counties in the U.S. offered pregnant people the opportunity to attempt labor after a previous cesarean section between 2016 and 2021, according to University of Massachusetts Amherst research that provides the most recent national look at this trend.

“Our findings confirm the difficulty individuals have expressed in accessing LAC [labor after cesarean],” concludes the research published recently in JAMA Network Open.

Counties with access to labor after cesarean were more prevalent in the Northeast and Western regions of the country. Large swaths of counties in the South and Midwest had “extremely limited access.” 

Though having labor with the goal of vaginal delivery is not the best choice for some pregnant people with a prior cesarean birth, vaginal birth after cesarean (VBAC) offers a shorter recovery and lower risk of infection, as well as a lower risk of complications in future pregnancies and maternal death, according to the American College of Obstetricians and Gynecologists (ACOG). 

“ACOG officially says that VBAC is a reasonable option for most people with a prior cesarean,” says Laura Attanasio, associate professor of health policy and management in the UMass Amherst School of Public Health and Health Sciences and senior author of the paper.

Metropolitan areas were most likely to offer LAC due to the availability of one or more hospitals staffed with the required specialists. Even then, the research notes, access may be hindered by other barriers, such as a lack of health insurance and transportation.

When limiting to counties that have a hospital offering obstetric services, LAC access rose to 30%. “So even when we’re looking only at counties that have obstetric care, less than a third of them offer access to labor after cesarean,” Attanasio says.

The rate of access to labor after cesarean held steady across the nation at 16% of counties from 2016 to 2021, according to the UMass Amherst research. Yet the national VBAC rate actually increased — from 12.4% in 2016 to 14.2% in 2021, according to the March of Dimes Perinatal Data Center

“One major finding was that access was pretty low and was not increasing over this time period,” Attanasio says. “Given that VBAC has increased over this time period, this suggests that VBAC rates are increasing in the places where VBAC is available rather than coming from more places offering labor after cesarean. Access is not expanding, at least at the county level.”

Attanasio was the advisor to lead author Brittany Ranchoff, a graduate of the Ph.D. program in health policy and management who worked on the paper as part of her dissertation. Other co-authors are Dr. Sarah Goff, professor and chair of health policy and management, and Elizabeth Bertone-Johnson, professor of epidemiology.

The researchers used birth certificate data to examine all births in every county in the U.S. from 2016-21. Birth certificates include information on mode of delivery. Attanasio and team point to several reasons that access for LAC is so low despite the current ACOG guidelines. 

In addition to hospitals with no obstetric services, another impediment occurs in hospitals with obstetric services that can’t guarantee immediate access to a cesarean surgery, which is the appropriate setting for LAC, according to ACOG guidelines.

Other big barriers may be the results of shifting clinical guidelines in the past few decades and the comfort, or lack thereof, of providers and medical liability insurers.

“There was a swing in the early 2000s to not having a vaginal birth after cesarean and then a recognition around 2010 that for a lot of people there might be clinical benefits and better outcomes to having a vaginal birth after cesarean, so it should be an option for more people,” Attanasio says. “But there’s been a lag in access catching up with this.

One of the concerns for providers and hospitals is around liability—if there’s someone attempting a vaginal birth after cesarean and it ends in a negative outcome.”

About the University of Massachusetts Amherst  

The flagship of the commonwealth, the University of Massachusetts Amherst is a nationally ranked public land-grant research university that seeks to expand educational access, fuel innovation and creativity, and share and use its knowledge for the common good. Founded in 1863, UMass Amherst sits on nearly 1,450-acres in scenic Western Massachusetts and boasts state-of-the-art facilities for teaching, research, scholarship, and creative activity. The institution advances a diverse, equitable, and inclusive community where everyone feels connected and valued—and thrives, and offers a full range of undergraduate, graduate and professional degrees across 10 schools and colleges, and 100 undergraduate majors.  

 


 

Mouse neurons that identify friends in need and friends indeed



Kobe University
250826-Takumi-Empathy-Collage 

image: 

Kobe University neuroscientist TAKUMI Toru and his team identified in mice a type of neuron that acts as a switch to control empathetic behavior, modulating the preference for social targets and thus in making social choices. “This finding is an important step toward understanding the neural basis of human sociality,” he says.

view more 

Credit: Kobe University, created with material from Brennan Burling via Unsplash, Understanding Animal Research, National Institutes of Health




A special set of neurons directs mice’s attention to or away from their peers, depending on the situation. The Kobe University discovery has implications for finding causes for neuropsychiatric conditions such as autism spectrum disorder or schizophrenia.

Social interactions abound with decisions: How much time do we spend with a friend? Do we prioritize time with a friend who looks distressed? Like for all behavior, there are specialized clusters of neurons in the brain that are responsible for fine-tuning such complex behavior, and it is known that developmental defects in these areas are related to neuropsychiatric disorders such as autism spectrum disorder or schizophrenia.

Kobe University neuroscientist TAKUMI Toru has a long history of research on discovering the neurological basis of these disorders. He says, “We have previously identified in mice a neuron cluster that’s active during social interaction and now we wanted to clarify the role of a specific kind of signal-modulating cell, so-called ‘PV interneurons,’ that we knew are there.” Using an endoscopic camera with its lens implanted directly into the brain of genetically modified mice, Takumi’s team was able to record in real time which neurons were active during different activities. In addition, they also introduced genetic modifications that allowed them to specifically tune down the activity of the target neurons.

In the scientific journal Cell Reports,  the Kobe University neuroscientists, in collaboration with SATO Masaaki of Kyoto Institute of Technology, now report that mice whose PV interneurons were inhibited exhibited two interesting behavioral characteristics. First, they failed to become familiar with their peers. Normal mice spend less time with individuals they already know than with strangers they meet for the first time, but the ones with inhibited PV interneurons would spend just as much time with peers as with strangers. And second, normal mice, when given the choice between two peers, one stressed and one unstressed, would spend more time with the stressed one. The inhibited mice, however, did not exhibit this consolation behavior.

“Our findings are the first to demonstrate that these particular cells act as a switch in the ‘social cell’ network to control empathetic behavior,” explains Takumi. In a separate experiment, where mice were allowed to freely interact with individuals they met for the first time, inhibited mice did not exhibit any differences from normal ones. This demonstrates that the role of PV interneurons is not so much connected to social behavior in general, but in modulating the preference for social targets and thus in making social choices.

Takumi says about the wider implications of this study: “This finding is an important step toward understanding the neural basis of human sociality. Abnormalities in PV interneurons have been reported in model animals and patient brains with autism spectrum disorder and schizophrenia. In the future, further comparative studies between mice and humans may lead to new treatment strategies.”

This research was funded by the Japan Society for the Promotion of Science (grants 23K27359, 24H02315, 23K14673, 24H00904, 23H04233, 23KK0132, 24K22036, 24H00620, 24H01241), the Japan Agency for Medical Research and Development (grant JP21wm0425011), the Japan Science and Technology Agency (grants JPMJMS2299, JPMJMS229B), the National Center of Neurology and Psychiatry (grant 6-9), the Takeda Science Foundation and the Taiju Life Social Welfare Foundation. It was conducted in collaboration with researchers from Hokkaido University and the Kyoto Institute of Technology.

Kobe University is a national university with roots dating back to the Kobe Higher Commercial School founded in 1902. It is now one of Japan’s leading comprehensive research universities with nearly 16,000 students and nearly 1,700 faculty in 11 faculties and schools and 15 graduate schools. Combining the social and natural sciences to cultivate leaders with an interdisciplinary perspective, Kobe University creates knowledge and fosters innovation to address society’s challenges.